PubAg

Main content area

You searched for: Subject "drug therapy" Remove constraint Subject: "drug therapy"
Start Over

Search

14,023  Search Results

« Previous | 1 - 20 of 14,023 |
Number of results to display per page

Search Results

1. Clinical outcomes of teicoplanin use in the OPAT setting

Author:
Dabrowski, Hannah; Wickham, Helena; De, Surjo; Underwood, Jonathan; Morris-Jones, Stephen; Logan, Sarah; Marks, Michael; Pollara, Gabriele
Source:
International journal of antimicrobial agents 2020 v.55 no.3 pp. 105888
ISSN:
0924-8579
Subject:
drug therapy,   etc   ; Enterococcus; ceftriaxone; patients;     Show all 4 Subjects
Abstract:
... Teicoplanin possesses several convenient properties for use in the delivery of outpatient parenteral antimicrobial therapy (OPAT) services. However, its use is not widespread and data on its efficacy in the OPAT setting are limited. Here we present a case series of patients undergoing OPAT care being treated by either teicoplanin-based (n = 107) or ceftriaxone-based (n = 191) antibiotic regimens. ...
DOI:
10.1016/j.ijantimicag.2020.105888
PubMed:
31923571
PubMed Central:
PMC7068648

2. Delayed asymptomatic progressive intraventricular pneumocephalus in a dog following craniotomy

Author:
Hicks, J.; Stewart, G.; Kent, M.; Platt, S.
Source:
Thejournal of small animal practice 2020 v.61 no.5 pp. 316-320
ISSN:
0022-4510
Subject:
drug therapy,   etc   ; dogs; magnetic resonance imaging;     Show all 3 Subjects
Abstract:
... Delayed pneumocephalus developed in a 9‐year‐old dog following transfrontal craniotomy and implantation of an experimental local chemotherapy into a partially resected oligodendroglioma, but the animal appeared to be asymptomatic. MRI evidence of increasing intracranial pressure, including progressive ventricular dilatation and compression of periventricular parenchyma, led to the recommendation f ...
DOI:
10.1111/jsap.12858

3. The paroxysmal depolarization shift in epilepsy research

Author:
Hotka, Matej; Kubista, Helmut
Source:
The international journal of biochemistry & cell biology 2019 v.107 pp. 77-81
ISSN:
1357-2725
Subject:
drug therapy,   etc   ; epilepsy; research;     Show all 3 Subjects
Abstract:
... Several shortcomings with currently available pharmacotherapy of epilepsy necessitate the search for new drug targets. Paroxysmal depolarization shifts (PDS) represent the cellular correlates of electrographic (e.g. interictal) spikes. While the ionic basis of PDS is understood in great detail, controversy exists regarding their proposed implication in epilepsy. To address this issue and to consid ...
DOI:
10.1016/j.biocel.2018.12.006

4. In vitro effects of lonidamine and 6-aminonicotinamide against Echinococcus granulosussensu stricto and Echinococcus multilocularis

Author:
Xin, Qi; Yuan, Miaomiao; Li, Huanping; Song, Xiaoxia; Lu, Jun; Jing, Tao
Source:
Veterinary research 2020 v.51 no.1 pp. 29
ISSN:
1297-9716
Subject:
drug therapy,   etc   ; Echinococcus multilocularis; drugs; echinococcosis; larvae; zoonoses;     Show all 6 Subjects
Abstract:
... Echinococcosis is a zoonotic disease caused by cestode species of the genus Echinococcus, which demonstrates considerable medical and veterinary concerns. The development of novel drugs for echinococcosis treatment is urgently needed. In this study, we demonstrated that lonidamine (LND) and 6-aminonicotinamide (6-AN) exhibited considerable in vitro effects against both larval- and adult-stage of E ...
DOI:
10.1186/s13567-020-00744-6
PubMed:
32101153
PubMed Central:
PMC7045558

5. Anticancer mechanisms of metformin: A review of the current evidence

Author:
Zhao, Bin; Luo, Jie; Yu, Tongyao; Zhou, Liangfu; Lv, Huanhuan; Shang, Peng
Source:
Life sciences 2020 v.254 pp. 117717
ISSN:
0024-3205
Subject:
drug therapy,   etc   ; antineoplastic activity; clinical trials; diabetes mellitus; metformin; neoplasms;     Show all 6 Subjects
Abstract:
... Metformin, a US Food and Drug Administration-approved “star” drug used for diabetes mellitus type 2, has become a topic of increasing interest to researchers due to its anti-neoplastic effects. Growing evidence has demonstrated that metformin may be a promising chemotherapeutic agent, and several clinical trials of metformin use in cancer treatment are ongoing. However, the anti-neoplastic effects ...
DOI:
10.1016/j.lfs.2020.117717

6. Nonsurgical and surgical management of metacarpo/metatarsophalangeal joint dorsal chip fracture in the Thoroughbred racehorse

Author:
Ramzan, P. H. L.; Wylie, C. E.
Source:
Equine veterinary journal 2020 v.52 no.3 pp. 399-403
ISSN:
0425-1644
Subject:
drug therapy,   etc   ; Thoroughbred; arthroscopy; forelimbs; observational studies; racehorses; radiography;     Show all 7 Subjects
Abstract:
... BACKGROUND: Arthroscopy is considered the treatment of choice for dorsal osteochondral chip fractures of the metacarpo/metatarsophalangeal (MCP/MTP) joints in the racehorse; however, there is no published research on non‐surgical management of this injury. OBJECTIVES: To compare clinical features, intra‐articular medication use and return to racing in Thoroughbred racehorses with non‐surgically (n ...
DOI:
10.1111/evj.13185

7. Doxorubicin-polyglycerol-nanodiamond conjugates disrupt STAT3/IL-6-mediated reciprocal activation loop between glioblastoma cells and astrocytes

Author:
Chen, Zhuo; Yuan, Shen-Jun; Li, Ke; Zhang, Quan; Li, Tong-Fei; An, Hui-Chao; Xu, Hua-Zhen; Yue, Yuan; Han, Min; Xu, Yong-Hong; Komatsu, Naoki; Zhao, Li; Chen, Xiao
Source:
Journal of controlled release 2020 v.320 pp. 469-483
ISSN:
0168-3659
Subject:
drug therapy,   etc   ; apoptosis; astrocytes; glioblastoma; interleukin-6; macrophages;     Show all 6 Subjects
Abstract:
... Astrocytes are key stromal components in glioblastoma (GBM) and have complex interactions with the GBM cells (GBC) promoting the survival, progression and therapy resistance of GBM. In this study, we first demonstrated the existence of a reciprocal activation loop mediated by the STAT3/IL-6 signaling between GBC and astrocytes. This loop of reciprocity was found to be initiated by the constitutive ...
DOI:
10.1016/j.jconrel.2020.01.044

8. Chemotherapy Induces Cancer-Fighting B Cells

Author:
Liu, Zhida; Fu, Yang-Xin
Source:
Cell 2020 v.180 no.6 pp. 1037-1039
ISSN:
0092-8674
Subject:
drug therapy,   etc   ; B-lymphocytes; T-lymphocytes; complement; immunity; neoplasms;     Show all 6 Subjects
Abstract:
... Tumor-infiltrating B cells are heterogeneous, and their roles in tumor immunity are controversial. In this issue of Cell, Lu and colleagues demonstrate that chemotherapy-induced complement signals promote the generation of ICOSL⁺B cells, which enhance tumor-specific T cell responses. ...
DOI:
10.1016/j.cell.2020.02.046

9. Retrospective comparison of first‐line adjuvant anthracycline vs metronomic‐based chemotherapy protocols in the treatment of stage I and II canine splenic haemangiosarcoma

Author:
Treggiari, Elisabetta; Borrego, Juan F.; Gramer, Irina; Valenti, Paola; Harper, Aaron; Finotello, Riccardo; Toni, Cristina; Laomedonte, Priscilla; Romanelli, Giorgio
Source:
Veterinary and comparative oncology 2020 v.18 no.1 pp. 43-51
ISSN:
1476-5810
Subject:
drug therapy,   etc   ; adjuvants; dogs; medical records; patients; retrospective studies;     Show all 6 Subjects
Abstract:
... Splenectomy followed by adjuvant chemotherapy is commonly used to treat canine splenic haemangiosarcoma (HSA), although it is unclear if different treatment protocols may have a similar efficacy. The objective of this retrospective study was to assess outcome in dogs with stage I and II splenic HSA treated with either first‐line adjuvant anthracycline (AC) or metronomic (MC)‐based chemotherapy pro ...
DOI:
10.1111/vco.12548

10. Identification of drug resistance associated ncRNAs based on comprehensive heterogeneous network

Author:
Huang, Yu-e; Zhou, Shunheng; Liu, Haizhou; Zhou, Xu; Yuan, Mengqin; Hou, Fei; Wang, Lihong; Jiang, Wei
Source:
Life sciences 2020 v.243 pp. 117256
ISSN:
0024-3205
Subject:
drug therapy,   etc   ; antineoplastic agents; drug resistance; microRNA; neoplasm cells; neoplasms;     Show all 6 Subjects
Abstract:
... Chemotherapy and molecularly targeted therapy are main strategies for treatment of cancers. However, long-term treatment makes cancer cells acquire resistance to anti-cancer drugs, which severely limits the effects of cancer treatment. NcRNAs, especially miRNAs and lncRNAs, have been reported to play key roles in drug resistance and could restore drug responses in resistant cells.We presented a ne ...
DOI:
10.1016/j.lfs.2020.117256

11. The Journey to Discovering a Flatworm Target of Praziquantel: A Long TRP

Author:
Park, Sang-Kyu; Marchant, Jonathan S.
Source:
Trends in parasitology 2020 v.36 no.2 pp. 182-194
ISSN:
1471-4922
Subject:
drug therapy,   etc   ; Schistosoma; blood flukes; drugs; ion channels; praziquantel; schistosomiasis;     Show all 7 Subjects
Abstract:
... Infections caused by parasitic flatworms impose a considerable worldwide health burden. One of the most impactful is schistosomiasis, a disease caused by parasitic blood flukes. Treatment of schistosomiasis has relied on a single drug – praziquantel (PZQ) – for decades. The utility of PZQ as an essential medication is, however, intertwined with a stark gap in our knowledge as to how this drug work ...
DOI:
10.1016/j.pt.2019.11.002
PubMed:
31787521
PubMed Central:
PMC6937385

12. A glance over doxorubicin based-nanotherapeutics: From proof-of-concept studies to solutions in the market

Author:
Gonçalves, Mara; Mignani, Serge; Rodrigues, João; Tomás, Helena
Source:
Journal of controlled release 2020 v.317 pp. 347-374
ISSN:
0168-3659
Subject:
drug therapy,   etc   ; adverse effects; case studies; doxorubicin; markets; nanomaterials; pharmacokinetics;     Show all 7 Subjects
Abstract:
... Cancer is one of the leading causes of death worldwide and, as such, efforts are being done to find new chemotherapeutic drugs or, alternatively, novel approaches for the delivery of old ones. In this scope, when used as vehicles for drugs, nanomaterials may potentially maximize the efficacy of the treatment and reduce its side effects, for example by a change in drug's pharmacokinetics, cell targ ...
DOI:
10.1016/j.jconrel.2019.11.016

13. Patterns and predictors of exercise behavior during 24 months of follow-up after a supervised exercise program during breast cancer chemotherapy

Author:
An, Ki-Yong; Kang, Dong-Woo; Morielli, Andria R.; Friedenreich, Christine M.; Reid, Robert D.; McKenzie, Donald C.; Gelmon, Karen; Mackey, John R.; Courneya, Kerry S.
Source:
The international journal of behavioral nutrition and physical activity 2020 v.17 no.1 pp. 23
ISSN:
1479-5868
Subject:
drug therapy,   etc   ; breast neoplasms; counseling; guidelines; patients; physical fitness; regression analysis; strength training;     Show all 8 Subjects
Abstract:
... BACKGROUND: Understanding the longer-term exercise behavior of patients with breast cancer after chemotherapy is important to promote sustained exercise. The purpose of the current study was to report the longer-term patterns and predictors of exercise behavior in patients with breast cancer who exercised during chemotherapy. METHODS: In the Combined Aerobic and Resistance Exercise (CARE) Trial, 3 ...
DOI:
10.1186/s12966-020-00924-9
PubMed:
32059728
PubMed Central:
PMC7023725

14. Therapeutic use of cannabis and cannabinoids: an evidence mapping and appraisal of systematic reviews

Author:
Montero-Oleas, Nadia; Arevalo-Rodriguez, Ingrid; Nuñez-González, Solange; Viteri-García, Andrés; Simancas-Racines, Daniel
Source:
BMC complementary medicine and therapies 2020 v.20 no.1 pp. 12
ISSN:
2662-7671
Subject:
drug therapy,   etc   ; Alzheimer disease; Parkinson disease; anorexia; cannabinoids; epilepsy; glaucoma; neoplasms; pain; sclerosis; systematic review; vomiting;     Show all 12 Subjects
Abstract:
... BACKGROUND: Although cannabis and cannabinoids are widely used with therapeutic purposes, their claimed efficacy is highly controversial. For this reason, medical cannabis use is a broad field of research that is rapidly expanding. Our objectives are to identify, characterize, appraise, and organize the current available evidence surrounding therapeutic use of cannabis and cannabinoids, using evid ...
DOI:
10.1186/s12906-019-2803-2
PubMed:
32020875
PubMed Central:
PMC7076827

15. All systems go: converging synthetic biology and combinatorial treatment for CAR-T cell therapy

Author:
Lanitis, Evripidis; Coukos, George; Irving, Melita
Source:
Current opinion in biotechnology 2020 v.65 pp. 75-87
ISSN:
0958-1669
Subject:
drug therapy,   etc   ; Adenoviridae; T-lymphocytes; antigens; monoclonal antibodies; neoplasms; radiotherapy; synthetic biology; vaccines;     Show all 9 Subjects
Abstract:
... Synthetic biology has been transformative to the treatment of advanced hematological malignancies by chimeric antigen receptor (CAR)-engineered T cells. A range of obstacles are now understood to limit the responses of solid epithelial-derived tumors to CAR therapy. For example, inefficient tumor homing and a fortified stroma can restrain the number of CAR-T cells reaching the tumor bed. Upon tran ...
DOI:
10.1016/j.copbio.2020.01.009

16. A host-guest drug delivery nanosystem for supramolecular chemotherapy

Author:
Hu, Xin-Yue; Gao, Jie; Chen, Fang-Yuan; Guo, Dong-Sheng
Source:
Journal of controlled release 2020 v.324 pp. 124-133
ISSN:
0168-3659
Subject:
drug therapy,   etc   ; adverse effects; aromatic hydrocarbons; fluorescence; image analysis; methotrexate; nanocarriers; uptake mechanisms;     Show all 8 Subjects
Abstract:
... Supramolecular chemotherapy is currently a new strategy to improve the therapeutic efficacy as well as overcome the side effects of traditional chemotherapy. Herein, a supramolecular chemotherapy platform based on the pegylated guanidinium-modified calix[5]arene pentadodecyl ether (GC5A-12C) nanoassembly was prepared. Three commercially available antitumor drugs: oxaliplatin, methotrexate and chlo ...
DOI:
10.1016/j.jconrel.2020.05.008

17. A tunable and injectable local drug delivery system for personalized periodontal application

Author:
Wang, Bing; Wang, Jiamian; Shao, Jinlong; Kouwer, Paul H.J.; Bronkhorst, Ewald M.; Jansen, John A.; Walboomers, X. Frank; Yang, Fang
Source:
Journal of controlled release 2020 v.324 pp. 134-145
ISSN:
0168-3659
Subject:
drug therapy,   etc   ; doxycycline; drug delivery systems; drugs; electrospraying; hydrogels; inflammation; microparticles; patients; phenotype;     Show all 10 Subjects
Abstract:
... In periodontal treatment, patient differences in disease phenotype and treatment responses are well documented. Therefore, therapy duration and dosage should be tailored to the requirements of individual patients. To facilitate such personalized medication, a tunable and controllable system is needed to deliver drugs directly into the diseased periodontal pockets. The current study established a s ...
DOI:
10.1016/j.jconrel.2020.05.004

18. In situ forming implants exposed to ultrasound enhance therapeutic efficacy in subcutaneous murine tumors

Author:
Jeganathan, Selva; Budziszewski, Emily; Bielecki, Peter; Kolios, Michael C.; Exner, Agata A.
Source:
Journal of controlled release 2020 v.324 pp. 146-155
ISSN:
0168-3659
Subject:
drug therapy,   etc   ; bioactive properties; drug delivery systems; drugs; mice; nanoparticles; neoplasm progression; neoplasms; ultrasonics; United States;     Show all 10 Subjects
Abstract:
... In situ forming implants (ISFIs) allow for a high initial intratumoral concentration and sustained release of the chemotherapeutic. However, clinical translation is impeded primarily due to limited drug penetration from the tumor/boundary interface and poor intratumoral drug retention. Therapeutic ultrasound (TUS) has become a popular approach for improving drug penetration of transdermal devices ...
DOI:
10.1016/j.jconrel.2020.05.003

19. Activated Wnt/β-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer

Author:
Bian, Pan; Dou, Zhongling; Jia, Zhaohui; Li, Wensheng; Pan, Dong
Source:
Life sciences 2020 v.254 pp. 116816
ISSN:
0024-3205
Subject:
drug therapy,   etc   ; beta catenin; carcinogenesis; cell proliferation; drug resistance; humans; prostatic neoplasms; ubiquitin-protein ligase; ubiquitination;     Show all 9 Subjects
Abstract:
... Docetaxel is commonly used to treat hormone-refractory prostate cancer (HRPC), but its clinical efficacy is limited by drug resistance, with the molecular mechanisms remaining elusive. The E3 ubiquitin ligase EDD modifies substrate proteins through ubiquitination and is involved in the regulation of cell proliferation and tumorigenesis. However, its role in docetaxel resistance of prostate cancer ...
DOI:
10.1016/j.lfs.2019.116816

20. Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) in non-small cell lung cancer

Author:
Zeng, Zhi; Wang, Zi-yao; Li, Yu-kun; Ye, Dong-mei; Zeng, Juan; Hu, Jia-li; Chen, Pi-feng; Xiao, Jiao; Zou, Juan; Li, Zhen-hua
Source:
Life sciences 2020 v.254 pp. 117325
ISSN:
0024-3205
Subject:
drug therapy,   etc   ; carcinogenesis; chemical structure; gene expression; lung neoplasms; prognosis; transcription factors;     Show all 7 Subjects
Abstract:
... Nuclear factor erythroid 2 (NF-E2)-related factor 2 (Nrf2) is a transcription factor that can regulate downstream target gene expression. Kelch-like ECH-associated protein 1 (Keap1) negatively regulates Nrf2 activation and translocation to target its 26S proteasomal degradation. It has been widely reported that the Keap1/Nrf2 pathway is associated with tumorigenesis, chemotherapy resistance and pr ...
DOI:
10.1016/j.lfs.2020.117325